Neuroblastoma: Issues in Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Grupp, Stephan A ^a,b   Asgharzadeh, Shahab ^c   Yanik, Gregory A ^d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; BUSULFAN; CARBOPLATIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; ETOPOSIDE; IRINOTECAN; ISOTRETINOIN; MELPHALAN; MONOCLONAL ANTIBODY; MYCN PROTEIN; THIOTEPA; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BRAIN SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVOR; CD34 SELECTION; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME LOSS; CYTOLOGY; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; ENGRAFTMENT; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; INFLAMMATION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MAXIMUM TOLERATED DOSE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROBLASTOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84855413824     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.020     Document Type: Article

References (78)

1. Bagatell R., Rumcheva P., London W.B., et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005, 23:8819-8827.
2. Simon T., Spitz R., Faldum A., Hero B., Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004, 26:791-796.
3. Grupp S.A., Stern J.W., Bunin N., et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000, 18:2567-2575.
4. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment ofhigh-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341:1165-1173.
5. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
6. Cheung N.V., Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991, 9:1050-1058.
7. Dini G., Lanino E., Garaventa A., et al. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol 1991, 9:962-969.
8. Dini G., Philip T., Hartmann O., et al. Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group. Bone Marrow Transplant 1989, 4(Suppl 4):42-46.
9. Kushner B.H., O'Reilly R.J., Mandell L.R., Gulati S.C., LaQuaglia M., Cheung N.K. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991, 9:274-279.
10. Matthay K.K. Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone Marrow Transplant 1996, 18(Suppl 3):S21-S24.
11. Matthay K.K., O'Leary M.C., Ramsay N.K., et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer 1995, 31A:572-575.
12. Pole J.G., Casper J., Elfenbein G., et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991, 9:152-158.
13. Philip T., Ladenstein R., Lasset C., et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997, 33:2130-2135.
14. Yu A.L., Gilman A.L., Ozkaynak M.F., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363:1324-1334.
15. Philip T., Ladenstein R., Zucker J.M., et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993, 67:119-127.
16. Grupp S.A., Stern J.W., Bunin N., et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol 2000, 35:696-700.
17. Kletzel M., Katzenstein H.M., Haut P.R., et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002, 20:2284-2292.
18. Powell J.L., Bunin N.J., Callahan C., Aplenc R., Griffin G., Grupp S.A. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 2004, 33:651-657.
19. George R.E., Li S., Medeiros-Nancarrow C., et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006, 24:2891-2896.
20. Ladenstein R.L., Poetschger U., Luksch R., et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: results from the HR-NBL1/SIOPEN trial. J Clin Oncol 2011, 29(suppl). abstr 2.
21. Rill D.R., Santana V.M., Roberts W.M., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380-383.
22. Reynolds C.P., Seeger R.C., Vo D.D., Black A.T., Wells J., Ugelstad J. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986, 46:5882-5886.
23. Seeger R.C., Vo D.D., Ugelstad J., Reynolds C.P. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res 1986, 211:285-293.
24. Donovan J., Temel J., Zuckerman A., et al. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol 2000, 35:677-682.
25. Kreissman S.G., Villablanca J.G., Seeger R.C., et al. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study. J Clin Oncol 2008, 26(suppl). abstr 10011.
26. Ambros P.F., Ambros I.M., Brodeur G.M., et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009, 100:1471-1482.
27. Schmidt M.L., Lal A., Seeger R.C., et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005, 23:6474-6480.
28. Baker D.L., Schmidt M.L., Cohn S.L., et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010, 363:1313-1323.
29. Simon T., Hero B., Faldum A., et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011, 11:21.
30. Berthold F., Boos J., Burdach S., et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005, 6:649-658.
31. Cheung N.K., Kushner B.H., Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am 2001, 15:853-866.
32. Matthay K.K., Reynolds C.P., Seeger R.C., et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group Study. J Clin Oncol 2009, 27:1007-1013.
33. Pearson A.D., Pinkerton C.R., Lewis I.J., et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008, 9:247-256.
34. Simon T., Berthold F., Borkhardt A., Kremens B., De Carolis B., Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011, 56:578-583.
35. Matthay K.K., Tan J.C., Villablanca J.G., et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006, 24:500-506.
36. Seeger R.C., Brodeur G.M., Sather H., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
37. Fong C.T., Dracopoli N.C., White P.S., et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 1989, 86:3753-3757.
38. Maris J.M., White P.S., Beltinger C.P., et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995, 55:4664-4669.
39. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005, 353:2243-2253.
40. Bown N., Cotterill S., Lastowska M., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999, 340:1954-1961.
41. Vandesompele J., Speleman F., Van Roy N., et al. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?. Med Pediatr Oncol 2001, 36:5-10.
42. Ohira M., Nakagawara A. Global genomic and RNA profiles for novel risk stratification of neuroblastoma. Cancer Sci 2010, 101:2295-2301.
43. Fischer M., Spitz R., Oberthur A., Westermann F., Berthold F. Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 2008, 220:137-146.
44. Janoueix-Lerosey I., Schleiermacher G., Michels E., et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009, 27:1026-1033.
45. Oberthuer A., Hero B., Berthold F., et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010, 28:3506-3515.
46. De Preter K., Vermeulen J., Brors B., et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010, 16:1532-1541.
47. Asgharzadeh S., Pique-Regi R., Sposto R., et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006, 98:1193-1203.
48. Seeger R.C., Reynolds C.P., Gallego R., Stram D.O., Gerbing R.B., Matthay K.K. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000, 18:4067-4076.
49. Burchill S.A., Lewis I.J., Abrams K.R., et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001, 19:1795-1801.
50. Cheung I.Y., Cheung N.K. Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Pediatr Oncol 2001, 36:210-212.
51. Cheung I.Y., Feng Y., Gerald W., Cheung N.K. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 2008, 14:7020-7027.
52. Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 2008, 26:5443-5449.
53. Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., et al. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem 2009, 55:1316-1326.
54. Stutterheim J., Zappeij-Kannegieter L., Versteeg R., Caron H.N., van der Schoot C.E., Tytgat G.A. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer 2011, 47:1193-1202.
55. Beiske K., Burchill S.A., Cheung I.Y., et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009, 100:1627-1637.
56. Naranjo A., Parisi M.T., Shulkin B.L., et al. Comparison of (1)(2)(3)I-metaiodobenzylguanidine (MIBG) and (1)(3)(1)I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011, 56:1041-1045.
57. Wieland D.M., Mangner T.J., Inbasekaran M.N., Brown L.E., Wu J.L. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 1984, 27:149-155.
58. Treuner J., Feine U., Niethammer D., et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1984, 1:333-334.
59. Hoefnagel C.A., Voute P.A., de Kraker J., Marcuse H.R. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987, 28:308-314.
60. Lumbroso J.D., Guermazi F., Hartmann O., et al. Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 1988, 271:689-705.
61. Parisi M.T., Greene M.K., Dykes T.M., Moraldo T.V., Sandler E.D., Hattner R.S. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol 1992, 27:768-773.
62. Shulkin B.L., Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998, 39:679-688.
63. Shapiro B., Copp J.E., Sisson J.C., Eyre P.L., Wallis J., Beierwaltes W.H. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985, 26:576-585.
64. Claudiani F., Stimamiglio P., Bertolazzi L., et al. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q J Nuclear Med 1995, 39:21-24.
65. Matthay K.K., Yanik G., Messina J., et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007, 25:1054-1060.
66. DuBois S.G., Matthay K.K. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008, 35(Suppl 1):S35-S48.
67. Yanik G.A., Levine J.E., Matthay K.K., et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for thetreatment of neuroblastoma. J Clin Oncol 2002, 20:2142-2149.
68. Miano M., Garaventa A., Pizzitola M.R., et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 2001, 27:571-574.
69. Gaze M.N., Chang Y.C., Flux G.D., Mairs R.J., Saran F.H., Meller S.T. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005, 20:195-199.
70. DuBois SG, Chesler L, Groshen S, al. E. Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy consortium study. Adv Neuroblastoma Res (ANR) Conf. 2010:202.
71. Ady N., Zucker J.M., Asselain B., et al. A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995, 31A:256-261.
72. Matthay K., Edeline V., Lumbroso J., et al. Correlation of earlymetastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003, 21:2486-2491.
73. Messina J., Cheng S.-C., Franc B., et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006, 47:865-874.
74. Ladenstein R., Philip T., Lasset C., et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998, 16:953-965.
75. Perel Y., Conway J., Kletzel M., et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999, 21:13-18.
76. Katzenstein H., Cohn S., Shore R., et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004, 22:3909-3915.
77. Yanik G., Parisi M.T., Naranjo A., et al. Analyses of MIBG scoring as a prognostic indicator in patients with Stage 4 neuroblastoma. A Children's Oncology Group (COG A3973) report. Adv Neuroblastoma Res (ANR) Conf 2010, 102.
78. Fish J.D., Grupp S.A. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 2008, 41:159-165.